Business
ACADIA Pharmaceuticals to Present at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor
About this update from Acadia Pharmaceuticals Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming virtual investor conferences:\n\n\nCiti 15th Annual BioPharma Virtual Conference\nDate: Wednesday, September 9, 2020\nPanel: Emerging Therapies for Psychiatric Disorders at 1:30 p.m. Eastern Time\n\n\nMorgan Stanley 18th Annual Global Healthcare Conference\nDate: Monday, September 14, 2020\nFireside chat presentation: 3:45 p.m. Eastern Time\n\n\nCantor Virtual Global Healthcare Conference\nDate: Wednesday, September 16, 2020\nFireside chat presentation: 11:20 a.m. Eastern Time\n\n\nThese conferences will all be held virtually. Live webcasts of the panel and presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.\n\n\nAbout ACADIA Pharmaceuticals\nACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA’s development efforts are focused on pimavanserin for additional neuropsychiatric conditions, trofinetide for Rett syndrome, ACP-044 for pain management and an early-stage muscarinic receptor program. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20200902005382/en/\n\nMedia Contact:\nACADIA Pharmaceuticals Inc.\nEric Endicott\n(858) 914-7161\[email protected]\n\n\nInvestor Contact:\nACADIA Pharmaceuticals Inc.\nMark Johnson, CFA\n(858) 261-2771\[email protected]\n\nSource: ACADIA Pharmaceuticals Inc.","length":3780,"tagName":"div"}]